140 related articles for article (PubMed ID: 2789098)
1. The effect of bispecific monoclonal antibody recognizing both hepatoma-specific membrane glycoprotein and anthracycline drugs on the metastatic growth of hepatoma AH66.
Tsukada Y; Ohkawa K; Hibi N; Tsuzuki K; Oguma K; Satoh H
Cancer Biochem Biophys; 1989 May; 10(3):247-56. PubMed ID: 2789098
[TBL] [Abstract][Full Text] [Related]
2. Specific targeting of adriamycin conjugates with monoclonal antibodies to hepatoma associated antigens to intrahepatic tumors in athymic mice.
Adler R; Hurwitz E; Wands JR; Sela M; Shouval D
Hepatology; 1995 Nov; 22(5):1482-7. PubMed ID: 7590667
[TBL] [Abstract][Full Text] [Related]
3. [Importance of the conjugated antibody for the induction of selective effect of adriamycin conjugated with anti AFP monoclonal antibody and entrapped in liposomes against AFP producing tumors].
Konno H; Kumai K; Tsubouchi T; Ishibiki K; Abe O; Tadakuma T; Yasuda T; Nagaike K; Hosokawa S; Sakaguchi S
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2213-7. PubMed ID: 2472119
[TBL] [Abstract][Full Text] [Related]
4. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model.
Iwahashi T; Okochi E; Ariyoshi K; Watabe H; Amann E; Mori S; Tsuruo T; Ono K
Cancer Res; 1993 Nov; 53(22):5475-82. PubMed ID: 8106147
[TBL] [Abstract][Full Text] [Related]
5. [Production of adriamycin covalent binding to monoclonal antibody OC-859 and its anti-tumor activities].
Zhang L
Zhonghua Fu Chan Ke Za Zhi; 1991 Nov; 26(6):346-8, 387. PubMed ID: 1804604
[TBL] [Abstract][Full Text] [Related]
6. In vitro cytotoxicity of the conjugate adriamycin with anti-sarcoma monoclonal antibody 19-24.
Mohamed G; Kuzmanoff KM; Stastny JJ; Das Gupta TK
Anticancer Res; 1992; 12(2):529-32. PubMed ID: 1580569
[TBL] [Abstract][Full Text] [Related]
7. [The antitumor effect of adriamycin conjugated with monoclonal antibody against gastric cancer in vitro and in vivo].
Zhang YT; Wang NQ; Li N; Liu T; Dong ZW
Yao Xue Xue Bao; 1992; 27(5):325-30. PubMed ID: 1442051
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
9. Establishment and serial quantification of intrahepatic xenografts of human hepatocellular carcinoma in severe combined immunodeficiency mice, and development of therapeutic strategies to overcome multidrug resistance.
Leveille-Webster CR; Arias IA
Clin Cancer Res; 1996 Apr; 2(4):695-706. PubMed ID: 9816220
[TBL] [Abstract][Full Text] [Related]
10. [Internalization of antibody-targeted immunonanoparticles into human hepatoma cells and its reversal effect on MDR].
Liu X; Wang X; Wei D; Cai M; Li G
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jul; 34(3):431-4. PubMed ID: 12910681
[TBL] [Abstract][Full Text] [Related]
11. [Experimental study on targeting therapy of human hepatocellular carcinoma in nude mice using adriamycin-anti-transferrin receptor conjugate].
Wang F; Li S; Lin J
Zhonghua Zhong Liu Za Zhi; 1995 Sep; 17(5):354-7. PubMed ID: 8697974
[TBL] [Abstract][Full Text] [Related]
12. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effect of treatment with polyclonal or monoclonal antibodies to alpha-fetoprotein that have been conjugated to daunomycin via a dextran bridge: studies with an alpha-fetoprotein-producing rat hepatoma tumor model.
Tsukada Y; Ohkawa K; Hibi N
Cancer Res; 1987 Aug; 47(16):4293-5. PubMed ID: 2440563
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells.
Russoniello C; Somasundaram C; Schlom J; Deo YM; Keler T
Clin Cancer Res; 1998 Sep; 4(9):2237-43. PubMed ID: 9748144
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug.
Inoh K; Muramatsu H; Torii S; Ikematsu S; Oda M; Kumai H; Sakuma S; Inui T; Kimura T; Muramatsu T
Jpn J Clin Oncol; 2006 Apr; 36(4):207-11. PubMed ID: 16611663
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy with bispecific antibodies.
Thielemans KM
Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
[TBL] [Abstract][Full Text] [Related]
17. The use of daunomycin-antibody immunoconjugates in managing soft tissue sarcomas: nude mouse xenograft model.
Stastny JJ; Das Gupta TK
Cancer Res; 1993 Dec; 53(23):5740-4. PubMed ID: 8242630
[TBL] [Abstract][Full Text] [Related]
18. Targeted adriamycin delivery to MXT-B2 metastatic mammary carcinoma cells by transferrin liposomes: effect of adriamycin ADR-to-lipid ratio.
Lopez-Barcons LA; Polo D; Llorens A; Reig F; Fabra A
Oncol Rep; 2005 Nov; 14(5):1337-43. PubMed ID: 16211306
[TBL] [Abstract][Full Text] [Related]
19. [Biodistribution of monoclonal antibody and Fab fragment and antitumor effect of their conjugates on hepatoma xenografts].
Li J; Zhen Y; Yang Z
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1994 Oct; 16(5):328-33. PubMed ID: 7720121
[TBL] [Abstract][Full Text] [Related]
20. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
Demanet C; Brissinck J; Leo O; Moser M; Thielemans K
Cancer Res; 1994 Jun; 54(11):2973-8. PubMed ID: 8187084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
